Epigenomics Successfully Completes Clinical Study In Lung Cancer Diagnosis

BERLIN and SEATTLE -- Epigenomics AG, a molecular diagnostics company focusing on the development and commercialization of products for cancer based on DNA methylation, today announced that it successfully completed a clinical study in its lung cancer program. The study was run in close collaboration with Prof. Dr. Christian Witt and Dr. Bernd Schmidt at the Charite -- Universitatsmedizin Berlin, Germany. The clinical study of 84 patient samples demonstrated that a panel of two proprietary biomarkers detected 79% of lung cancers in bronchial lavage specimens at specificity of 95%, i.e. only two false positives results were obtained in 45 patients with benign lung diseases. Bronchial lavage specimens are routinely taken d...